Health● Low33m ago · Nov 19, 2026, 4:30 AM
A new drug that doubles pancreatic cancer survival arrives in Europe: patients ask Spain to accelerate its funding
GlobeAlert Desk · curated from Infobae · Argentina · Western Europe
Daraxonrasib has managed to increase median overall survival from 6.7 months to 12.4 months.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
1 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Health
Not flagged as developing.
More from Argentina
World1h agoArgentina, wife of former Red Brigades member Bertulazzi arrested: she allegedly helped her husband escapeRepubblica · ItalySci & Tech2h agoGTA 6 can now be played in Argentina: on which consoles it is available, how much it costs, and when it will be released for PC (no spoilers)La Nación · ArgentinaBusiness6h agoCAAP outlines $7.3B Argentina investment program as domestic passenger use fee moves to $9 on December 10Seeking Alpha TechBusiness7h agoAccording to Diego Estévez, half of the 2026 inflation was imported and Argentina faces a historic opportunityInfobae · Argentina
More in Health
Health33m agoIn immersion, episode 3 | Carpe Diem House: sick, but happyLa Presse · CanadaHealth33m agoIn immersion, episode 4 | Carpe Diem House: Mr. Lamothe no longer wants to dieLa Presse · CanadaHealth50m agoBiodiversity, health, society: one same futureLibération · FranceHealth1h ago‘The abuse I copped was phenomenal’: researchers accuse tobacco companies of intimidation tactics to silence criticsGuardian Australia · Australia